# MOTS-c — Research Peptide Profile

> A mitochondria-encoded peptide that mimics exercise through AMPK activation. Human exercise data, mechanism, research dosing & metabolic effects.

Source: https://peptpedia.org/peptide/mots-c | Published: 2025-12-02 | Last updated: 2026-08-04

MOTS-c is a peptide encoded by mitochondrial DNA — one of the first discovered — that acts as an exercise-mimetic signal, activating AMPK and improving glucose uptake in muscle. Human studies show it rises during exercise; interventional evidence is largely in animals. Human dosing data is minimal and it is unapproved.

## Overview

MOTS-c is a 16-amino-acid peptide (sequence: MRWQEMGYIFYPRKLR) encoded in the 12S rRNA region of [mitochondrial DNA](/peptide/ss-31), discovered in 2015 as the first mitochondrial signal peptide to translocate to the cell nucleus and directly regulate nuclear gene expression. It activates [AMPK signaling](/research/mots-c-mitochondrial) to regulate glucose uptake and lipid metabolism, improves insulin sensitivity, and is secreted during exercise to mediate metabolic adaptations. Primary research applications include obesity, type 2 diabetes, insulin resistance, and [age-related metabolic decline](/compare/foxo4-dri-vs-mots-c).

## Molecular Profile

- **Category:** metabolic
- **Molecular formula:** C101H152N28O22S2
- **Molecular weight:** 2174.59 g/mol
- **CAS number:** 1627580-64-6
- **Amino acid sequence:** MRWQEMGYIFYPRKLR
- **Also known as:** Mitochondrial ORF of the 12S rRNA-c
- **Half-life:** Not precisely established
- **Solubility:** Soluble in water
- **Storage:** Store at -20°C.

## Mechanism of Action

MOTS-c improves metabolic homeostasis by enhancing glucose regulation and insulin sensitivity. It activates the AMPK pathway and affects folate-methionine cycle metabolism, influencing cellular energy status. The peptide can translocate to the nucleus and regulate gene expression, representing novel mitochondria-to-nucleus communication.

## Key Research Findings

- MOTS-c is one of the first peptides discovered to be encoded by mitochondrial DNA rather than nuclear DNA, revealing that mitochondria actively communicate with the rest of the cell through signaling molecules.
- MOTS-c activates the AMPK pathway and enhances glucose uptake into skeletal muscle, closely mimicking the metabolic effects of physical exercise and earning it the label of exercise mimetic.
- Circulating MOTS-c levels increase during exercise in humans, suggesting the peptide may naturally mediate some of the metabolic benefits attributed to physical activity.
- MOTS-c has demonstrated the ability to prevent diet-induced obesity in animal models even without changes in food intake, by increasing energy expenditure and improving insulin sensitivity.

## MOTS-c Pharmacokinetics: An Endogenous Signal Without a PK Map

This section requires an honest framing: MOTS-c has no published formal pharmacokinetic characterization in any species. No peer-reviewed study reports a plasma half-life, clearance, volume of distribution, or absolute bioavailability for exogenous MOTS-c. What the literature provides instead is endogenous physiology — the peptide circulates at measurable levels in humans and responds to exercise — plus rodent dosing regimens that produce systemic effects.

### Endogenous Circulation and the Exercise Response

The best-documented kinetic fact about MOTS-c is that it is a genuine circulating peptide whose levels move with physiological state.

- Exercise-Induced Release: In young men, an acute exercise bout induced endogenous MOTS-c expression in skeletal muscle (P=0.0098) and raised serum MOTS-c measured by ELISA (P=0.0011 and P=0.0021 across sampling comparisons) — direct evidence that working muscle releases this mitochondrial peptide into circulation (PMID 33473109).
- Independent Replication With a Caveat: In a randomized trial comparing 45 minutes of cycling at 70% of VO2max against resistance exercise, circulating humanin rose significantly while MOTS-c showed only a trend toward increase, and resting plasma levels of both peptides did not correlate with fitness measures — the exercise-MOTS-c signal is real but modest and protocol-dependent (PMID 34351816).
- Class-Level Context: Reviews of mitochondrial-derived peptides place MOTS-c alongside humanin as exercise-responsive circulating signals while emphasizing that their secretion dynamics, tissue targets, and elimination routes are only beginning to be mapped (PMID 34520826).

### What Animal Studies Reveal About Exposure

All interventional exposure data come from rodents, at doses far above anything endogenous physiology produces.

- Systemic Effects From Injected Doses: The discovery study showed that MOTS-c circulates and acts on metabolic tissues; the mouse protocols that prevented diet-induced obesity and insulin resistance through AMPK activation used 15 mg/kg/day intraperitoneal injection (PMID 25738459).
- Intermittent Dosing Suffices in Mice: Late-life intermittent MOTS-c treatment (three times weekly, initiated at 23.5 months of age) increased physical capacity and healthspan measures in mice, indicating durable pharmacodynamic effect from non-continuous dosing (PMID 33473109).
- The Dose-Translation Problem: Effective rodent doses are milligram-per-kilogram injections producing supraphysiological exposure, and because plasma concentrations were not measured in those animals, the exposure multiple over endogenous levels cannot be calculated (PMID 25738459).

### The Measurement Gap

Any specific MOTS-c half-life figure should be treated with suspicion — none exists in the primary literature.

- No Formal Human PK: No published study measures the half-life, clearance, or bioavailability of exogenous MOTS-c in humans, and no human clinical trial of the peptide has been published; the human data that exist are exercise-physiology and observational measurements of endogenous levels (PMID 33473109).
- No Published Analog PK Either: Even for clinical-stage MOTS-c analogs such as CB4211, no PubMed-indexed pharmacokinetic data has appeared — the peptide class's entire clinical exposure record remains unpublished (PMID 34520826).
- Practical Implication: Research dosing protocols extrapolate directly from mouse milligram-per-kilogram regimens, and the weekly milligram-scale schedules circulating in research communities have no pharmacokinetic validation behind them (PMID 25738459).

## Safety & Tolerability

No human safety or clinical trials of MOTS-c have been conducted; all interventional evidence is from animal studies, and the pharmacokinetics of exogenous MOTS-c (bioavailability, distribution, half-life, metabolism) are incompletely characterized. Because MOTS-c has pleiotropic effects across multiple tissues, the full physiological response to supraphysiological dosing is difficult to predict.

**Human data status:** MOTS-c was only discovered in 2015. There are no human interventional, safety, or efficacy trials; human evidence is limited to observational and genetic-association studies.

**Regulatory status:** Not approved for human use by any regulatory agency; an early-stage research compound.

- In mouse models, MOTS-c improved insulin sensitivity and protected against diet-induced obesity via AMPK activation; these are animal findings, not human results. (evidence tier: animal; [PMID 25738459](https://pubmed.ncbi.nlm.nih.gov/25738459/))
- Human evidence is limited to observational and genetic-association studies — for example, a mitochondrial MOTS-c variant (K14Q) has been linked to exceptional longevity in human cohorts — which cannot establish safety or causal efficacy. (evidence tier: human-observational; [PMID 26289118](https://pubmed.ncbi.nlm.nih.gov/26289118/))

## Dosing Information (Research Context)

Research protocols typically use 2mg administered via subcutaneous injection. Studies have employed various dosing frequencies depending on research objectives. The peptide is reconstituted in bacteriostatic water for injection.

| Route | Dose | Frequency | Notes |
| --- | --- | --- | --- |
| Subcutaneous (research) | 10–15 mg/week | As per protocol | Common research community protocol; no human clinical trial data to reference |

## Researched Effects

- **Metabolic Regulation** (evidence: moderate): Research demonstrates MOTS-c's significant role in metabolic homeostasis through enhancement of glucose uptake, improved insulin sensitivity, and optimization of cellular energy metabolism across multiple tissue types. Studies in animal models have documented 30-50% improvements in glucose tolerance tests following MOTS-c administration, with effects comparable to established diabetes medications in some experimental paradigms. The peptide regulates metabolism through modulation of the folate-methionine cycle, affecting one-carbon metabolism and thereby influencing methylation reactions critical for gene expression and cellular function. Research has shown MOTS-c levels decline with age, correlating with age-related metabolic dysfunction and suggesting the peptide may play a protective role against metabolic decline. These metabolic health improvement properties have positioned MOTS-c as a promising research compound for type 2 diabetes mechanism studies, insulin resistance investigations, and understanding the fundamental connections between mitochondrial function and whole-body metabolic regulation.
- **Exercise Mimetic Effects** (evidence: moderate): Groundbreaking research has established MOTS-c as an exercise-induced mitochondrial peptide that may replicate some of the metabolic benefits of physical activity, leading to its classification as a potential exercise mimetic compound. Studies demonstrate that circulating MOTS-c levels increase significantly during exercise in both young and older individuals, with the peptide appearing to mediate some of exercise's beneficial effects on glucose metabolism and insulin sensitivity. Animal studies have shown that MOTS-c administration improves running endurance, enhances exercise capacity, and activates skeletal muscle adaptations similar to those produced by endurance training. The peptide's effects appear particularly relevant for aging populations, as research indicates MOTS-c may help maintain metabolic health and physical function in contexts where exercise capacity is limited. These exercise mimetic properties have generated significant interest in MOTS-c for research into aging interventions, physical performance optimization, and therapeutic approaches for individuals unable to exercise due to disability or illness.
- **AMPK Activation** (evidence: moderate): Research demonstrates MOTS-c potently activates AMP-activated protein kinase (AMPK), the master cellular energy sensor that coordinates metabolic responses to energy stress and exercise throughout the body. Studies show MOTS-c treatment increases phosphorylated AMPK levels in skeletal muscle, liver, and adipose tissue, triggering downstream effects including enhanced fatty acid oxidation, increased glucose uptake, and mitochondrial biogenesis. The peptide's AMPK-activating mechanism appears to involve inhibition of the folate cycle, leading to accumulation of AICAR (an endogenous AMPK activator) and subsequent kinase activation through AMP-mimetic pathways. Research indicates MOTS-c's AMPK activation is sustained over time and produces metabolic effects similar to those achieved by pharmacological AMPK activators like metformin and AICAR. These AMPK pathway activation properties have established MOTS-c as an important research tool for investigating cellular energy sensing mechanisms, metabolic adaptation pathways, and development of novel AMPK-targeted therapeutics for metabolic disease.
- **Obesity Protection** (evidence: preliminary): Animal studies demonstrate MOTS-c provides significant protection against diet-induced obesity through multiple mechanisms including enhanced fat oxidation, increased energy expenditure, and prevention of excessive lipid accumulation in metabolic tissues. Research has shown that MOTS-c administration prevents weight gain in mice fed high-fat diets, with treated animals maintaining body weights 15-20% lower than untreated controls despite equivalent caloric intake. The peptide appears to increase thermogenesis and browning of white adipose tissue, converting metabolically inactive fat stores to more metabolically active brown-like fat that burns calories for heat production. Studies indicate MOTS-c may protect against hepatic steatosis (fatty liver disease) by reducing fat accumulation in the liver while improving systemic lipid profiles including reduced triglycerides and improved cholesterol ratios. These obesity protection properties position MOTS-c as a valuable research compound for investigating metabolic syndrome interventions, understanding the mitochondrial contribution to body weight regulation, and developing novel approaches to obesity treatment and prevention.
- **Mitochondrial Function Enhancement** (evidence: moderate): Research reveals MOTS-c's unique role as a mitochondrial-encoded peptide that enhances mitochondrial function and promotes mitochondrial biogenesis across multiple tissue types, representing a novel form of retrograde mitochondrial signaling. Studies demonstrate the peptide translocates from mitochondria to the nucleus under metabolic stress conditions, where it directly regulates nuclear gene expression involved in stress response and metabolic adaptation. Research shows MOTS-c treatment increases mitochondrial DNA content, enhances oxidative phosphorylation capacity, and improves cellular ATP production efficiency in skeletal muscle and other metabolically active tissues. The peptide appears to protect mitochondria from oxidative damage while enhancing their ability to respond to metabolic challenges, contributing to improved cellular resilience and energy homeostasis. These mitochondrial function optimization properties have important implications for aging research, mitochondrial disease mechanisms, and understanding the fundamental role of mitochondrial peptides in cellular communication and metabolic health.

## Research Applications

- Metabolic Research
- Diabetes Studies
- Exercise Physiology
- Aging Research
- Mitochondrial Biology
- Obesity Research

## Key Studies

### MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline

Reynolds JC, Lai RW, et al. — *Nature Communications* (2021) — [PMID 33473109](https://pubmed.ncbi.nlm.nih.gov/33473109/) | [doi:10.1038/s41467-020-20790-0](https://doi.org/10.1038/s41467-020-20790-0)

This landmark Nature Communications study established MOTS-c as an exercise-responsive mitochondrial peptide that may counteract age-related physical decline and metabolic dysfunction. Researchers demonstrated that MOTS-c levels increase during exercise in humans and that exogenous MOTS-c administration in aged mice improves physical capacity and metabolic health to levels comparable to young animals. The study showed that MOTS-c treatment enhanced running endurance by approximately 20% in older mice while improving glucose tolerance and insulin sensitivity parameters. Molecular analysis revealed MOTS-c activates skeletal muscle stress response pathways and promotes cellular adaptations similar to those induced by exercise training. These findings positioned MOTS-c as a potential therapeutic candidate for age-related metabolic decline and physical frailty, with implications for exercise mimetic drug development and healthy aging research.

### The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis

Lee C, Zeng J, et al. — *Cell Metabolism* (2015) — [PMID 25738459](https://pubmed.ncbi.nlm.nih.gov/25738459/) | [doi:10.1016/j.cmet.2015.02.009](https://doi.org/10.1016/j.cmet.2015.02.009)

This foundational Cell Metabolism publication introduced MOTS-c as a novel mitochondrial-derived peptide with potent metabolic regulatory functions, establishing an entirely new class of mitochondrial signaling molecules. Researchers identified MOTS-c as a 16 amino acid peptide encoded within the mitochondrial 12S rRNA gene that circulates in the bloodstream and targets metabolic tissues throughout the body. The study demonstrated that MOTS-c treatment prevents diet-induced obesity and insulin resistance in mice through activation of AMPK signaling and modulation of the folate-methionine cycle. Mechanistic analysis revealed MOTS-c accumulates in the cytoplasm and nucleus of target cells, where it regulates gene expression involved in glucose metabolism and stress response. These discoveries opened new research directions in mitochondrial biology, metabolic regulation, and the development of mitochondrial peptide-based therapeutics for metabolic disease.

## Frequently Asked Questions

### What makes MOTS-c unique among peptides?

MOTS-c is the first identified peptide encoded in the mitochondrial genome (rather than nuclear DNA) that can translocate to the cell nucleus and regulate gene expression. This represents a fundamentally new type of intracellular signaling pathway: retrograde mitochondria-to-nucleus communication. While the mitochondrial genome is tiny (37 genes), it now appears to encode functional signaling peptides—MOTS-c was the first discovered, followed by Humanin. This discovery expanded our understanding of mitochondria from passive 'energy factories' to active signaling organelles that communicate metabolic status to the genome.

### How does MOTS-c relate to exercise?

A 2020 study found that circulating MOTS-c levels increase significantly during both aerobic and resistance exercise in humans, with levels correlating with exercise intensity. MOTS-c appears to be secreted by contracting muscle mitochondria in response to metabolic stress, and may mediate some of exercise's systemic metabolic benefits: AMPK activation in liver and adipose tissue, improved insulin-stimulated glucose uptake, and upregulation of genes involved in fatty acid oxidation. MOTS-c has been proposed as an 'exercise mimetic' in the sense that it can replicate specific downstream metabolic signatures of exercise—though it cannot replicate the cardiovascular, bone density, or psychological effects of actual physical activity.

### How does MOTS-c activate AMPK and what does that mean?

AMPK (AMP-activated protein kinase) is the cell's master energy sensor—activated when cellular energy (ATP) is low relative to AMP, it shifts metabolism toward energy production and away from energy storage. MOTS-c activates AMPK indirectly by inhibiting the folate-methionine cycle, which depletes AICAR (an endogenous AMPK activator)—this creates an AICAR-like accumulation that triggers AMPK activation. AMPK activation produces multiple metabolic effects: increased glucose uptake via GLUT4 translocation, enhanced fatty acid oxidation, mitochondrial biogenesis (PGC-1α activation), and suppression of gluconeogenesis. These are the same metabolic pathways activated by metformin and AICAR, explaining why MOTS-c has been compared to both compounds.

### Does MOTS-c decline with age?

Yes. A study measuring circulating MOTS-c in 781 individuals found that serum MOTS-c levels decline significantly with age, with older individuals having approximately 40% lower MOTS-c concentrations than young adults. The decline correlates with reduced muscle mass, impaired insulin sensitivity, and increased adiposity characteristic of metabolic aging. Interestingly, the study also found that healthy centenarians had higher MOTS-c levels than age-matched controls, suggesting that maintained MOTS-c secretion capacity may be associated with exceptional longevity—though causality cannot be established from this correlation.

### What are the limitations of current MOTS-c research?

MOTS-c research has several critical limitations. First, the peptide was only discovered in 2015, so the research base is less than 10 years old. Second, all efficacy data comes from mouse studies—no human clinical trials have been completed or published. Third, the pharmacokinetics of exogenous MOTS-c administration (bioavailability, distribution, half-life, metabolism) are incompletely characterized. Fourth, MOTS-c has pleiotropic effects across multiple tissues, making predicting the full physiological response to supraphysiological dosing complex. As a research peptide, it represents a genuinely exciting area of mitochondrial biology but is many years from any clinical application.

### What are MOTS-c's effects on insulin sensitivity in animal models?

Mouse studies have documented MOTS-c's potent insulin-sensitizing effects: (1) In diet-induced obese mice, MOTS-c administration (15 mg/kg/day IP) reversed high-fat diet-induced insulin resistance as measured by glucose tolerance test and insulin tolerance test; (2) Skeletal muscle glucose uptake improved through GLUT4 translocation—MOTS-c increased AMPK-driven GLUT4 membrane insertion in muscle cells independently of insulin signaling; (3) Hepatic glucose production (gluconeogenesis) was suppressed through AMPK activation in liver tissue. These combined effects produce significant reductions in fasting glucose and improved post-meal glucose clearance. The magnitude of effect in mouse models is substantial and comparable to metformin.

### Is MOTS-c considered an exercise mimetic?

MOTS-c has been described as a partial exercise mimetic because exogenous MOTS-c administration replicates several molecular signatures of endurance exercise: AMPK activation in multiple tissues, enhanced fatty acid oxidation, improved mitochondrial efficiency, and increased mitochondrial biogenesis markers. A 2020 PNAS study demonstrated that exogenous MOTS-c improved exercise capacity in aged mice, paralleling the well-established ability of exercise training to improve aerobic capacity with aging. However, MOTS-c cannot replicate all aspects of exercise (cardiovascular adaptations, neuromuscular changes, bone density maintenance, psychological benefits). The 'mimetic' framing is mechanistically justified but should not be interpreted as a substitute for physical activity.

### What role does MOTS-c play in longevity and healthy aging?

A human observational study (N=781) found that centenarians (individuals over 100 years old) maintained MOTS-c serum levels comparable to 60-year-olds, while age-matched controls (80–90 years old) had substantially lower MOTS-c. A specific MOTS-c variant (K14Q) is enriched in Japanese centenarian populations—a genetic finding suggesting MOTS-c contributes to exceptional longevity. Additionally, MOTS-c polymorphisms associated with metabolic disease susceptibility have been identified in population genetics studies. These human genetic and epidemiological findings provide circumstantial but compelling evidence that MOTS-c signaling capacity may be one determinant of healthy metabolic aging and longevity, though no interventional human studies exist.

### What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded in the 12S rRNA region of mitochondrial DNA — one of the first discovered mitochondrial-derived peptides. It functions as an exercise-mimetic signal: it activates AMPK, improves glucose uptake in muscle, and human studies show it rises during exercise. Interventional evidence is largely in animals, human dosing data is minimal, and it is unapproved.

## Related Peptides

- [AOD-9604](https://peptpedia.org/peptide/aod-9604)

---

This content is for educational and research purposes only. It is not medical advice, and the compounds covered are research chemicals not approved for human use unless explicitly stated otherwise.

Cite this page: Peptpedia — Research Peptide Encyclopedia, https://peptpedia.org